Br J Anaesth:老年患者心脏手术后谵妄与术后脑供氧不足有关

2020-02-21 anesthGH “罂粟花”微信号

近红外光谱可无创测量局部脑氧饱和度。术中脑供氧不足与较差的神经预后相关。本研究旨在探讨老年患者心脏手术后谵妄是否与围手术期脑氧饱和度降低有关。

背景与目的

近红外光谱可无创测量局部脑氧饱和度。术中脑供氧不足与较差的神经预后相关。本研究旨在探讨老年患者心脏手术后谵妄是否与围手术期脑氧饱和度降低有关。

方  法

2015年至2017年期间,70岁及以上择期行体外循环心脏手术的患者被纳入本项单中心、前瞻性、观察研究。术前1天测量脑氧饱和度基础水平。手术期间及转入ICU后,连续监测脑氧饱和度至术后72h。使用混淆评估法评估ICU内的谵妄发生情况,并采用未校正分析和多变量逻辑回归评估与谵妄的相关性。

结 果

103名患者中有96例被纳入研究,29例(30%)出现谵妄。术中脑氧饱和度与术后谵妄无显着相关性。谵妄患者术后最低脑氧饱和度较低(P=0.001)。与非谵妄患者(9 [4]% 和14 [5]%;P=0.002 和P=0.001)相比,谵妄患者术后脑氧饱和度绝对和相对降低更明显(分别为13[6]%和19[9]%)。排除患者发生谵妄后的脑氧饱和度值,这些脑氧饱和度的差异不再存在。高龄、既往卒中史、EuroSCORE II较高、术前简易精神状态测试评分较低,以及术后脑氧饱和度较明显绝对降低与术后谵妄的发生率独立相关。

结 论

老年患者心脏手术后谵妄与术后脑氧饱和度绝对降低有关。这些差异在谵妄发作后表现得最为明显。

原始出处:

Eertmans W, De Deyne C, Genbrugge C, et al. Association between postoperative delirium and postoperative cerebral oxygen desaturation in older patients after cardiac surgery. [J]. Br J Anaesth. 2019 Dec 17. pii: S0007-0912(19)30802-5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633562, encodeId=249c163356261, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jul 17 06:08:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051524, encodeId=8ef22051524d4, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Apr 18 08:08:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307306, encodeId=9523130e3063f, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sun Feb 23 14:08:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379502, encodeId=015f3e950285, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 21 23:15:32 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-07-17 AspirantSuo
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633562, encodeId=249c163356261, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jul 17 06:08:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051524, encodeId=8ef22051524d4, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Apr 18 08:08:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307306, encodeId=9523130e3063f, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sun Feb 23 14:08:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379502, encodeId=015f3e950285, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 21 23:15:32 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633562, encodeId=249c163356261, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jul 17 06:08:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051524, encodeId=8ef22051524d4, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Apr 18 08:08:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307306, encodeId=9523130e3063f, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sun Feb 23 14:08:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379502, encodeId=015f3e950285, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 21 23:15:32 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1633562, encodeId=249c163356261, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Fri Jul 17 06:08:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051524, encodeId=8ef22051524d4, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sat Apr 18 08:08:00 CST 2020, time=2020-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1307306, encodeId=9523130e3063f, content=<a href='/topic/show?id=2fbb61104e6' target=_blank style='color:#2F92EE;'>#术后谵妄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61104, encryptionId=2fbb61104e6, topicName=术后谵妄)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5462342, createdName=sunmin0219, createdTime=Sun Feb 23 14:08:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=379502, encodeId=015f3e950285, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Feb 21 23:15:32 CST 2020, time=2020-02-21, status=1, ipAttribution=)]
    2020-02-21 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

一个不寻常的病例:心脏上的绣花针

注:本文整理自欧洲心脏杂志(EHJ)近期发表的一篇文章,原文作者来自四川大学华西医院。患者,女,55岁,因阵发性右上腹痛就诊,被诊断为胆结石。术前胸片显示心脏有致密条状阴影(下图A)。经胸和食管超声心动图证实致密条状阴影是异物(27毫米长),从右上到左下穿透室间隔,无室间分流。非增强CT显示在右心室和左心室以及室间隔(下图H和I)有异物。经过沟通后获悉,患者有把绣花针别在左胸前衣服上的习惯。17年

Thyroid:甲状腺功能与肝脏、心脏和肺脏纤维化风险

这项研究表明甲状腺功能低下与肝脏、心脏和肺脏慢性纤维化疾病的可能性增加有关。但是,证据主要基于横截面数据。需要进行前瞻性研究和随机临床试验来探究甲状腺激素及其类似物对纤维化发生发展的潜在功效。

“观肺”不可忘“护心”,心衰患者该如何应对“新冠”疫情?

新型冠状病毒肺炎(以下简称“新冠肺炎”)自2019年12月暴发,至今疫情蔓延至全国乃至全球多个国家及地区,给人们生活带来巨大影响。人群对新型冠状病毒普遍易感。但从各地报告来看,老年人感染后病情较重,特别是患有心血管系统疾病、呼吸系统疾病等慢性基础疾病的患者。

EUR HEART J-CARD PHA:全国登记资料的回顾性分析心肌梗死患者出血后的抗血栓治疗和主要不良心脏事件

本研究的目的是描述心肌梗死(MI)患者在发生出血事件后使用抗血栓治疗,以及发生重大心脏不良事件(MACE)的相关风险。

Sci Adv:程柯团队带来抗体药物靶向受损心脏新方法

来自北卡罗莱纳州立大学和北卡大学教堂山分校的一项研究报道了一种新型血小板微粒,可以实现将抗炎抗体药物靶向运输到缺血损伤心脏的效果。目前这项研究以封面文章的形式发表在《Science Advances》杂志上。程柯教授是文章的通讯作者,博士后研究员李振华博士为本文的第一作者。

Hypertension:肾脏去神经后心脏每搏量的变化

由此可见,在这项对顽固性高血压患者进行的研究中,与假手术患者相比,RDN导致心脏每搏量减少。